Clinical Trials Logo

Filter by:
NCT ID: NCT00846911 Completed - Bronchitis, Chronic Clinical Trials

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Start date: April 2008
Phase: N/A
Study type: Observational

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events. This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.

NCT ID: NCT00846001 Completed - Clinical trials for Ischemic Heart Failure

Resynchronization Surgery Combined Unified Efficacy

RESCUE
Start date: September 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare survivability and efficacy of the patients with severe ischemic heart failure after coronary artery bypass grafting alone and coronary artery bypass grafting with single-step implantation of CRT system (CABG alone vs CABG + CRT )

NCT ID: NCT00845728 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Exacerbation Study

INVIGORATE
Start date: March 2009
Phase: Phase 3
Study type: Interventional

This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks

NCT ID: NCT00845026 Completed - Schizophrenia Clinical Trials

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care (SOC) treatment. Lack of tolerability was defined as discontinuation due to adverse events (AEs). Patients who completed the active treatment phase were eligible to continue to an optional 28 weeks of treatment extension phase. This extension phase assessed key safety and efficacy measures.

NCT ID: NCT00844857 Completed - Bipolar Depression Clinical Trials

A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

Start date: April 2009
Phase: Phase 4
Study type: Interventional

The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. - Can this study drug make children with bipolar depression feel better? - Does this study drug work better than a placebo (sugar pill)? - Does this study drug cause side effects in children who take it? - Is this drug safe to use in children? (The study drug is a mixture of olanzapine and fluoxetine)

NCT ID: NCT00844649 Completed - Clinical trials for Metastatic Pancreatic Cancer

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Start date: March 1, 2009
Phase: Phase 3
Study type: Interventional

Phase III Metastatic Pancreatic Cancer

NCT ID: NCT00843492 Completed - Thrombosis, Venous Clinical Trials

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

FONDACAST
Start date: December 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by ultrasound, and pulmonary embolism (blood clots that migrate to the lungs) in patients with leg injuries below the knee that require a cast or other type of immobilization but not surgery.

NCT ID: NCT00841958 Completed - Myocardial Ischemia Clinical Trials

Endocardial Stem Cells Approach Efficacy

ESCAPE
Start date: February 2007
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to test that endocardial stem cells implantation in patients who have CAD, low ejection fraction and signs of HF without possibility of CABG and PCI or despite on previous revascularization improves long-term survival compared to MED alone

NCT ID: NCT00841672 Completed - Clinical trials for Moderate to Severe Hypertension

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis that the combination of aliskiren/amlodipine produces a superior reduction from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment.

NCT ID: NCT00840086 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

guardian™1
Start date: April 2009
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding episodes during surgical procedures.